SGLT2 inhibitors decrease glucose and sodium reabsorption in the proximal tubule, reducing intraglomerular pressure via enhanced tubuloglomerular feedback, thus alleviating glomerular hyperfiltration and improving renal hemodynamics in diabetic nephropathy [46,47,48]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.